MedTrace Logo

A Study of the Pharmacokinetics and Safety of Anaprazole Sodium in Special Populations

NCT07345689 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-01-16

No results posted yet for this study

Summary

The objective of this study is to evaluate the pharmacokinetic profile and safety of anaprazole sodium in adult subjects, particularly including the elderly and those with renal or hepatic impairment.

Conditions

  • Hepatic Insufficiency
  • Renal Insufficiency
  • Elderly

Interventions

DRUG

Anaprazole Sodium enteric-coated tablet

20 mg single dose

Sponsors & Collaborators

  • Xuanzhu Biopharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Hong Zhang, PhD · The First Bethune Hospital of Jilin University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-01-30
Primary Completion
2026-10-30
Completion
2027-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07345689 on ClinicalTrials.gov